 |
|
|
| |
Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
P Buggisch1, J Petersen1, S Mauss2, K Kowdley3, M Curry4, P Ruane5, D Ain5, N Tsai6, Y Lee7, M Natha8, E Eggleton8, B Kreter8, DM Brainard8, P Ingiliz9
1IFI Institut für Interdisziplinäre Medizin, Asklepios Klinik St. Georg, Hamburg Germany; 2Center for HIV and Hepatogastroenterology, Duesseldorf; 3Swedish Medical Center, Seattle, WA; 4Beth Israel, Boston MA;
5Ruane Medical Center and Liver Health, LA, CA; 6Queens Medical Center, Honolulu, HI; 7TRIO Health Analytics; 8Gilead Sciences Foster City, CA; 9Medizinisches Infektiologie Zentrum Berlin, Berlin
|
| |
|
|
|
|
|
